Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$3.09 - $4.56 $8,961 - $13,223
2,900 New
2,900 $11,000
Q2 2023

Aug 09, 2023

BUY
$3.21 - $5.06 $3,258 - $5,135
1,015 New
1,015 $3,000
Q4 2022

Feb 13, 2023

SELL
$4.35 - $6.17 $434 - $617
-100 Reduced 27.47%
264 $1,000
Q3 2022

Oct 27, 2022

BUY
$5.49 - $8.79 $1,998 - $3,199
364 New
364 $2,000
Q2 2022

Aug 01, 2022

SELL
$5.33 - $8.18 $1,103 - $1,693
-207 Closed
0 $0
Q1 2022

May 11, 2022

SELL
$5.5 - $9.19 $231 - $385
-42 Reduced 16.87%
207 $1,000
Q4 2021

Feb 11, 2022

BUY
$7.67 - $44.59 $1,549 - $9,007
202 Added 429.79%
249 $2,000
Q3 2021

Nov 10, 2021

BUY
$21.33 - $35.06 $682 - $1,121
32 Added 213.33%
47 $2,000
Q2 2021

Aug 05, 2021

BUY
$19.22 - $59.08 $288 - $886
15 New
15 $0

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $270M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.